Estrella Immunopharma, Inc. (NASDAQ:ESLA) Short Interest Update

Estrella Immunopharma, Inc. (NASDAQ:ESLA) was the recipient of a significant growth in short interest in November. As of November 30th, there was short interest totalling 37,700 shares, a growth of 158.2% from the November 15th total of 14,600 shares. Approximately 0.4% of the company’s stock are sold short. Based on an average daily volume of 137,400 shares, the days-to-cover ratio is presently 0.3 days.

Estrella Immunopharma Stock Down 3.3 %

ESLA traded down $0.04 on Friday, reaching $1.19. The company’s stock had a trading volume of 3,577 shares, compared to its average volume of 75,987. The stock has a 50 day moving average of $0.95 and a two-hundred day moving average of $1.11. The company has a market capitalization of $43.19 million, a price-to-earnings ratio of -4.59 and a beta of 0.46. Estrella Immunopharma has a fifty-two week low of $0.63 and a fifty-two week high of $3.23.

Estrella Immunopharma (NASDAQ:ESLA) last posted its quarterly earnings data on Friday, September 27th. The company reported ($0.13) earnings per share for the quarter.

About Estrella Immunopharma

Estrella Immunopharma, Inc, a preclinical-stage biopharmaceutical company, develops T-cell therapies for blood cancers and solid tumors in the United States. The company's lead product candidates include EB103 for the treatment of diffuse large B-cell lymphoma and is in pre clinical trial; and EB104 to treat diffuse large B-cell lymphoma and acute lymphocytic leukemia.